Completed PHASE1 INTERVENTIONAL 2-arm NCT00950638

A Study of ARC1905 (Anti-C5 Aptamer) in Subjects With Dry Age-related Macular Degeneration

A Phase I Study to Establish the Safety and Tolerability of ARC1905 (Anti-C5 Aptamer) in Subjects With Dry Age-related Macular Degeneration

Sponsor: Ophthotech Corporation

Conditions Dry Age-Related Macular Degeneration

Interventions Avacincaptad Pegol

Updated 11 times since 2017 Last updated: Mar 6, 2025 Started: Jul 16, 2009 Primary completion: Mar 24, 2011 Completion: Mar 24, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Dry Age-Related Macular Degeneration, this trial is completed. The trial is conducted by Ophthotech Corporation and has accumulated 11 data snapshots since 2009. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

11 versions recorded

Apr 2025 — Present [monthly]

Completed PHASE1
Mar 2025 — Apr 2025 [monthly]

Completed PHASE1
Sep 2024 — Mar 2025 [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Mar 2024 — Jul 2024 [monthly]

Completed PHASE1

▶ Show 6 earlier versions

Jan 2021 — Mar 2024 [monthly]

Completed PHASE1
Feb 2020 — Jan 2021 [monthly]

Completed PHASE1
Jun 2018 — Feb 2020 [monthly]

Completed PHASE1
Sep 2017 — Jun 2018 [monthly]

Completed PHASE1
Feb 2017 — Sep 2017 [monthly]

Completed PHASE1
Jan 2017 — Feb 2017 [monthly]

Completed PHASE1

First recorded

Jul 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Ophthotech Corporation

Data source: Astellas Pharma Inc

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• New York, United States